Investigational drug · Phase 2
scp776
Also called: all
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke (AIS).
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "scp776"
First trial start
2022
Oct 19, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "scp776", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke (AIS)
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "scp776" as an intervention, largest first.
- Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic StrokePivotal-lookingCompleted
Silver Creek PharmaceuticalsIndustry
NCT05585606 · 120 participants · Start Oct 19, 2022 · Primary completion Sep 15, 2025
Drug: Placebo; scp776 (1.9 mg/kg) and 3 more · For: Acute Ischemic Stroke (AIS)
Sites: Scottsdale, Arizona; Tucson, Arizona; Hartford, Connecticut · 22 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The selective IGF-1 fusion protein scp776 targets apoptotic cells and promotes recovery of ischemia/reperfusion injured tissues: Engineering and preclinical validation.
Pfaff SJ, Zhang Y, Olsen W, et al. · Biomed Pharmacother 2026
- Scp776, A Novel IGF-1 Fusion Protein for Acute Therapy to Promote Escape From Apoptosis in Tissues Affected by Ischemic Injury: 2 Randomized Placebo-Controlled Phase 1 Studies in Healthy Adults.
Pfaff SJ, O'Reilly T, Zhang Y, et al. · Clin Pharmacol Drug Dev 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.